COMPANY

AbelZeta Pharma

HQ: Rockville, MD (US office) source · abelzeta.com ↗

Also known as AbelZeta Inc. · 5 sources

Location: Rockville, MD (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Lupus Nephritis Systemic Sclerosis Systemic Sclerosis (Scleroderma) Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria Systemic Sclerosis Pulmonary Systemic Sclerosis With Lung Involvement Multiple Sclerosis Systemic Lupus Erythematosus Autoimmune Diseases Metastatic Non Small Cell Lung Cancer C-CAR168 C-TIL051

5Trials (company is sponsor)

Raises and deals from press releases

Deal AstraZeneca deal · amount not disclosed · announced Jan 19, 2026 Company release ↗
Source quote
- Jan 19, 2026 · Company release ↗
  “AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 30, 2026 Trial start Phase 2: C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy source ↗
Feb 29, 2024 Trial start Phase 1: C-TIL051 in Non-Small Cell Lung Cancer source ↗
2027-03 Trial start 1: A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc) source ↗
2027-02 Trial start Phase 1/Phase 2: A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis source ↗
2026-07 Trial start Phase 1/Phase 2: C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease source ↗

Upcoming milestones

2028-12 (ESTIMATED) · 1 · A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc) · NCT07854483
Dec 31, 2028 (ESTIMATED) · Phase 2 · C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy · NCT07729826
2030-02 (ESTIMATED) · Phase 1/Phase 2 · A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis · NCT07825389

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07854483	A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)	1	Not yet recruiting	2027-03	2028-12 (estimated)
NCT07825389	A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis	Phase 1/Phase 2	Not yet recruiting	2027-02	2030-02 (estimated)
NCT07729826	C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy	Phase 2	Not yet recruiting	Sep 30, 2026	Dec 31, 2028 (estimated)
NCT06935474	C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease	Phase 1/Phase 2	Withdrawn	2026-07	2029-05 (estimated)
NCT05676749	C-TIL051 in Non-Small Cell Lung Cancer	Phase 1	Terminated	Feb 29, 2024	Dec 30, 2025 (actual)